Winners And Losers In Q4: Comparing Biogen (NASDAQ:BIIB) To Other Therapeutics Stocks

Overview: Q4 Therapeutics Earnings Recap

Let’s take a closer look at how Biogen (NASDAQ:BIIB) and its competitors performed as the fourth quarter earnings season for therapeutics companies wraps up.

In the coming years, firms specializing in therapeutic solutions are expected to benefit from advancements in precision medicine—such as AI-driven drug discovery—and increasing demand for treatments addressing rare conditions. However, challenges remain, including heightened scrutiny over drug pricing, regulatory uncertainties, and stiff competition from larger pharmaceutical corporations.

Q4 Performance Highlights

Across the 11 therapeutics stocks monitored, the group delivered robust fourth-quarter results, with revenues surpassing consensus forecasts by 7.1%.

Share prices have shown resilience, rising an average of 6.4% since the latest earnings reports.

Biogen (NASDAQ:BIIB)

Established in 1978, Biogen has been at the forefront of developing therapies for complex neurological disorders, including multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and rare diseases.

For Q4, Biogen posted $2.28 billion in revenue, marking a 1.2% increase year-over-year and beating analyst projections by 3.6%. The company also exceeded expectations for both full-year and quarterly earnings per share.

Following the earnings announcement, Biogen’s stock rose 1.1% and is currently trading at $187.48.

Top Q4 Performer: Novavax (NASDAQ:NVAX)

Novavax leverages nanoparticle technology to create protein-based vaccines targeting infectious diseases, with a particular emphasis on COVID-19 and combination respiratory vaccines.

In Q4, Novavax reported $147.1 million in revenue—a 66.6% year-over-year increase—outpacing analyst estimates by 57.4%. The company delivered strong results, beating both revenue and earnings per share expectations.

Novavax achieved the highest revenue growth and the largest beat against analyst forecasts among its peers. The stock climbed 9.5% post-earnings and is now priced at $10.44.

United Therapeutics (NASDAQ:UTHR)

United Therapeutics was founded by a mother seeking solutions for her daughter’s pulmonary arterial hypertension. The company focuses on developing and marketing treatments for chronic lung diseases and other severe conditions, with an emphasis on pulmonary hypertension therapies.

For Q4, United Therapeutics reported $790.2 million in revenue, up 7.4% from the previous year but falling short of analyst expectations by 2.5%. The quarter was softer, missing revenue forecasts significantly.

Despite underperforming relative to analyst estimates, United Therapeutics’ stock surged 12% after the earnings release and is currently valued at $530.05.

Amgen (NASDAQ:AMGN)

Founded in 1980 during the early biotechnology era, Amgen is known for developing innovative treatments for serious illnesses such as cancer, osteoporosis, and autoimmune disorders.

Amgen reported $9.87 billion in revenue for Q4, an 8.6% increase year-over-year, beating analyst expectations by 4.1%. The company also exceeded both quarterly and full-year revenue guidance.

Amgen’s stock is up 10.6% since the earnings announcement and currently trades at $374.52.

Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals, founded in 1989, is dedicated to developing medicines that address the root causes of diseases, focusing on conditions like cystic fibrosis, sickle cell disease, and pain management.

In Q4, Vertex reported $3.19 billion in revenue, a 9.5% year-over-year increase, surpassing analyst estimates by 1.1%. The quarter was mixed, with a slight revenue beat but a notable miss on earnings per share.

Vertex’s stock has risen 4.3% since the earnings release and is currently trading at $485.02.

Looking for Strong Investment Opportunities?